Clinical Trial Update: Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site [Phase 2]

View source ↗

Summary

This update notes the termination of a Phase 2 study evaluating Carboplatin, Gemcitabine, and Capecitabine in carcinoma of unknown primary.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of Unknown Primary

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Gemzar (gemcitabine)
• Xeloda (capecitabine)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Carcinoma of Unknown Primary | Phase 2 | Status: TERMINATED